BackTcr2 Therapeutics Overview

Tcr2 Therapeutics Accounts Payable

Tcr2 Therapeutics's accounts payable is $6.3M.

Get informed when a big investor buys or sells

+ Follow
Accounts Payable
$6.32M
↑ 41.01% YoYΔ $1.84M vs prior year quarter

Peer trimmed avg / median

Loading

Tcr2 Therapeutics Accounts Payable History

Loading

Tcr2 Therapeutics vs. peers: Accounts Payable Comparison

Loading

Tcr2 Therapeutics Accounts Payable Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Tcr2 Therapeutics (TCRR) FAQ

As of the most recent data (March 2023), TCRR shows a accounts payable of $6.3M. That compares with $4.5M in the prior-year period — up 41.0% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, TCRR's accounts payable is now $6.3M (was $4.5M) — a 41.0% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Tcr2 Therapeutics is outperforming or lagging.

Tracking TCRR's accounts payable over time shows whether Tcr2 Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $6.3M That compares with $4.5M in the prior-year period — up 41.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this accounts payable page, Stockcircle has Tcr2 Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect accounts payable (currently $6.3M) with ownership activity and broader fundamentals.

Tcr2 Therapeutics's accounts payable is $6.3M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.